APT
is a Maryland-based biotechnology company that researches and develops antimicrobial therapeutics to treat multidrug-resistant infections... Read moreAPT
is a Maryland-based biotechnology company that researches and develops antimicrobial therapeutics to treat multidrug-resistant infections... Read more
Interim-CEO
Ian Hardy
News
Mar 21, 2024
Global Legal Chronicle
APT: BiomX's Merger with Adaptive Phage Therapeutics
Mar 18, 2024
centralcharts
APT: BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Mar 06, 2024
Globes
APT: Phage therapy co BiomX merges with APT, raises $50m
Jan 17, 2024
The Business Journals: Washington, D.C.
APT: Gaithersburg biotech initiates another round of layoffs as longtime CEO steps back
Jan 17, 2024
The Business Journals: Washington, D.C.
APT: Gaithersburg biotech initiates another round of layoffs as longtime CEO steps back
Jun 13, 2023
The Business Journals: Washington, D.C.
APT: Exclusive: Gaithersburg's Adaptive Phage Therapeutics raising $30M for superbug-killing therapy
May 25, 2023
SEC
Press Release: APT : Adaptive Phage Therapeutics, Inc. Received $12M in Equity Funding
May 24, 2023
BioSpace
APT: Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center
Jan 14, 2023
Pharmabiz
APT: APT announces patient dosing in PHAGE clinical trial evaluating bacteriophage therapy
Jan 12, 2023
The Business Journals: Washington, D.C.
APT: Md. biotech Adaptive Phage Therapeutics advances fight to wipe out superbugs in cystic fibrosis
APT Competitors
1
2
3
4
5
6
7